Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
about
Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremiaPreclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.Maraviroc: a review of its use in HIV infection and beyondChronic alcohol abuse and HIV disease progression: studies with the non-human primate modelA novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivoHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesGoing wild: lessons from naturally occurring T-lymphotropic lentivirusesDiscrepant amplification results during the development of an assay leads to reclassification of two AIDS reagent repository HIV-2 isolates as HIV-1.Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeysThe variable loop 3 in the envelope glycoprotein is critical for the atypical coreceptor usage of an HIV-1 strain.Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytesVaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaquesReceptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challengeMacrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophagesMultispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaquesInfectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCsIncreased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 alleleVaccination with live attenuated simian immunodeficiency virus causes dynamic changes in intestinal CD4+CCR5+ T cells.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Non-human primate models for AIDS vaccine research.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Nonpathogenic CCR2-tropic SIVrcm after serial passage and its effect on SIVmac infection of Indian rhesus macaques.Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts.Cloning and analysis of sooty mangabey alternative coreceptors that support simian immunodeficiency virus SIVsmm entry independently of CCR5.In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.In vitro characterization of primary SIVsmm isolates belonging to different lineages. In vitro growth on rhesus macaque cells is not predictive for in vivo replication in rhesus macaquesStable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.
P2860
Q24534959-F4E6B71A-9C11-4420-9E6A-2094278112EEQ24557545-BBCF7761-928B-4167-B07D-7EBD59B616B8Q24812967-7222615A-2324-41C6-8D2A-8D83D31912E9Q26778504-F0C3010F-B90C-411C-B66A-CA492B30D73AQ26852432-EEE0CC96-ED9D-4653-A46B-C6407E7DC6AAQ27313759-F7E45B81-42AF-4F26-A035-344F36A336AEQ29619015-5F1B8BBC-19B8-4D89-A1AB-B15C8320E3F1Q31066870-3C9B99F4-B40C-447E-AFBB-38085469280DQ33567901-E4C335C2-7E05-4EE2-9214-35842ACF03B8Q33619206-8CC23723-1F79-4DC9-B0FD-0166023EEEA6Q33711710-35C609C5-3510-46CC-8744-669D10ECBB8DQ33716586-148657E7-804A-40CD-9652-5E31FCD55298Q33717525-F75A3E84-368D-46ED-8555-C5586E3D550DQ33841288-C03B311C-B499-4998-83E5-25E32F9E29D7Q34010373-C3DDD0D3-4798-4E99-BDF1-BF180FBF3651Q34123595-1F60B59E-BB6B-4F83-A7AE-732A284842E1Q34178259-9CCAF493-53A1-44AB-98E1-F0D49D275003Q34226885-7481228E-5665-4378-BF6A-2390A30BC730Q34226966-771EC863-2276-4C03-9310-ABA654ED73F6Q34228494-9BB819BC-0956-42DB-87A6-48F94AC32047Q34332369-BDADEBDF-80F3-46C8-9CFE-5DD3381B3CCCQ34340428-33C0422D-AB86-4F9A-B677-9B4C95CCB492Q34545588-ADC5BDF8-4F05-4831-99A9-9B4A688F6D93Q34573745-ECC8B883-7ED5-43BF-B760-3B75FC30A171Q34611466-EE7BC674-9FB3-42CA-98BF-EE9A3257A146Q34715769-80232E9E-0296-421B-A448-D532C8218FCFQ34781878-570B902E-5EE0-4C2B-8578-C112C72261A8Q34976172-36BFE2B0-3A7F-428A-8C40-7573A89545ADQ34996958-00E6C254-AD9E-4E81-B5F9-24CD69E18646Q35141486-8D9A22BB-9F6C-4BF1-B210-AB921C637AA6Q35274968-0998AF62-10DB-47C5-A7D6-0E90D8F5182DQ35616028-A21A0A6D-2A67-4C93-BF8A-40788A50C337Q35665825-B7AE0A3C-7FF5-431D-B3D5-202791F7130CQ35666480-453F64F3-6367-4CB0-AF97-66CF3EBE57AFQ35738681-3163488F-7816-4BD2-A0C1-BAB8F4C55E54Q35919086-093368CC-AB87-46B3-BD8B-EAD7FAC01EA5Q35928777-2FDB2D3F-2E7F-450E-BAF0-39E6DED36774Q35933555-FD58966F-2284-4883-8E1B-281DE8D5FB09Q36371505-B0F49F93-8D5B-4273-BBAA-000DD0993612Q36399466-F94C74B4-3CB0-47E1-B268-D46C167E64E0
P2860
Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@ast
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@en
type
label
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@ast
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@en
prefLabel
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@ast
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@en
P2093
P2860
P1433
P1476
Use of inhibitors to evaluate ...... virus type 2 in primary cells.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.15.6893-6910.2000
P577
2000-08-01T00:00:00Z